Genetically adjusted PSA should also be evaluated in conjunction with other procedures used for prostate cancer detection, such as targeted magnetic resonance imaging, and explored as a criterion for refining selection of participants into screening trials. This evidence concerns the gene KLK3 and Familial prostate cancer.